Syndax Pharmaceuticals (SNDX) Short term Debt (2020 - 2024)

Syndax Pharmaceuticals' Short term Debt history runs 4 years deep, the most recent figure standing at $12.1 million for Q4 2024.

• On a quarterly basis, Short term Debt changed N/A year-over-year to $12.1 million in Q4 2024; TTM through Dec 2024 was $12.1 million, a N/A change from a year earlier, with the FY2024 full-year figure at $12.1 million, changed N/A from the prior year.
• Short term Debt improved to $12.1 million in Q4 2024 per SNDX's latest filing, from $7.2 million in the prior quarter.
• Across five years, Short term Debt topped out at $12.1 million in Q4 2024 and bottomed at $2.3 million in Q4 2020.
• The 4-year median for Short term Debt is $7.0 million (2021), against an average of $6.6 million.
• Biggest YoY gain for Short term Debt was 2.59% in 2022; the steepest drop was 22.97% in 2022.
• Year by year, Short term Debt stood at $2.3 million in 2020, then surged by 315.27% to $9.5 million in 2021, then slipped by 24.0% to $7.2 million in 2022, then jumped by 68.0% to $12.1 million in 2024.
• Per Business Quant, the three latest SNDX Short term Debt figures stand at $12.1 million (Q4 2024), $7.2 million (Q2 2022), and $3.6 million (Q1 2022).